This suggests that monoclonal antibodies against CD47 (if their side effects can be resolved), as well as inhibitors of PKA kinases and Src kinases, particularly specific inhibitors of Src kinase, may reduce T cell infiltration into inflammatory sites and thereby treat rheumatoid arthritis. The gene discussed is CD47; the disease is rheumatoid arthritis.